<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04858568</url>
  </required_header>
  <id_info>
    <org_study_id>RHM CAN1612</org_study_id>
    <nct_id>NCT04858568</nct_id>
  </id_info>
  <brief_title>Immune Responses to COVID-19 Vaccination in Lymphoma Patients</brief_title>
  <acronym>PROSECO</acronym>
  <official_title>PROSECO - A UK Multicentre Prospective Observational Study Evaluating COVID-19 Vaccine Immune Responses in Lymphoid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Southampton NHS Foundation Trust</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective observational study aims to evaluate the robustness and persistence of&#xD;
      immune responses to vaccination, define factors associated with impaired immune responses and&#xD;
      assess the incidence of COVID-19 infections in vaccinated individuals. To do this, we will&#xD;
      collect peripheral blood from patients with lymphoid cancers before and after their COVID-19&#xD;
      vaccination. The blood will be explored in the laboratory for antibodies to SARS-CoV-2 and&#xD;
      T-cell responses to the spike protein. Detailed clinical information will also be collated on&#xD;
      about their cancer and treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 11, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum IgG levels against SARS-CoV-2 post-COVID-19 vaccination and change over time.</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the robustness and persistence of anti-S IgG levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison between SARS-CoV-2 IgG responses with clinical parameters.</measure>
    <time_frame>12 months</time_frame>
    <description>Correlation between anti-S IgG between different lymphoma subtypes and the impact of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic COVID-19 with positive SARS-CoV-2 PCR results.</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the incidence of symptomatic, virologically proven COVID-19 in vaccinated individuals within 12 months of vaccine administration.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">592</enrollment>
  <condition>Classical Hodgkin Lymphoma</condition>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Primary Mediastinal B Cell Lymphoma</condition>
  <condition>High-grade B-cell Lymphoma</condition>
  <condition>Burkitt Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>Lymphoplasmacytic Lymphoma</condition>
  <condition>Nodular Lymphocyte Predominant Hodgkin Lymphoma</condition>
  <condition>Peripheral T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Hodgkin lymphoma</arm_group_label>
    <description>Diagnoses:&#xD;
Hodgkin lymphoma (classical Hodgkin lymphoma)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aggressive B-NHL</arm_group_label>
    <description>Diagnoses:&#xD;
Aggressive B-NHL (E.g. Diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, Burkitt lymphoma, de novo transformed lymphoma, follicular lymphoma grade 3b)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indolent B-NHL</arm_group_label>
    <description>Diagnoses:&#xD;
Indolent B-NHL (E.g.follicular lymphoma grades 1-3a, mantle cell lymphoma, marginal zone lymphoma, chronic lymphocytic leukaemia/small lymphocytic lymphoma, lymphoplasmacytic lymphoma, nodular lymphocyte predominant Hodgkin lymphoma)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peripheral T/NK-cell</arm_group_label>
    <description>Diagnoses:&#xD;
Peripheral T/NK-cell lymphomas (any mature T/NK cell malignancy)</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma Serum Peripheral blood mononuclear cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with a confirmed lymphoma diagnosis who is under the care of a secondary or&#xD;
        tertiary referral centre.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          1. Patients having a confirmed diagnosis of either:&#xD;
&#xD;
             A) Hodgkin lymphoma B) Aggressive B-cell lymphoma (e.g. Burkitt's lymphoma, diffuse&#xD;
             large B-cell lymphoma, grade 3b follicular lymphoma, de novo transformed follicular&#xD;
             lymphoma) C) Indolent B-cell lymphoma (e.g. all grades of follicular lymphoma except&#xD;
             grade 3b, marginal zone lymphoma, lymphoplasmacytic lymphoma, chronic or small&#xD;
             lymphocytic lymphoma, mantle cell lymphoma) D) Mature T/NK-cell malignancy (any&#xD;
             subtype)&#xD;
&#xD;
          2. Patient must be â‰¥ 18 years.&#xD;
&#xD;
          3. Patients will have provided written Informed Consent.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
        1) Serious medical or psychiatric illness likely to affect participation or that may&#xD;
        compromise the ability to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bedfordshire Hospitals NHS Foundation Trust</name>
      <address>
        <city>Bedford</city>
        <state>Bedfordshire</state>
        <zip>MK42 9DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portsmouth Hospitals University NHS Trust</name>
      <address>
        <city>Portsmouth</city>
        <state>Hampshire</state>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wye Valley NHS Trust</name>
      <address>
        <city>Hereford</city>
        <state>Herefordshire</state>
        <zip>HR1 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Newcastle Upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

